Entera Bio (NASDAQ:ENTX) Director Sean Ellis Buys 10,000 Shares of Stock

Entera Bio Ltd. (NASDAQ:ENTX) Director Sean Ellis bought 10,000 shares of the company’s stock in a transaction on Thursday, March 5th. The shares were bought at an average price of $1.23 per share, for a total transaction of $12,300.00. Following the completion of the acquisition, the director directly owned 188,098 shares in the company, valued at approximately $231,360.54. This trade represents a 5.61% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

Sean Ellis also recently made the following trade(s):

• On Monday, February 9th, Sean Ellis purchased 18,000 shares of Entera Bio stock. The stock was bought at an average cost of $1.24 per share, for a total transaction of $22,320.00.

Entera Bio Stock Up 6.4%

Entera Bio stock opened at $1.33 on Tuesday. The company has a 50 day moving average of $1.50 and a 200-day moving average of $1.96. Entera Bio Ltd. has a twelve month low of $1.00 and a twelve month high of $3.22. The stock has a market capitalization of $60.99 million, a PE ratio of -5.32 and a beta of 1.83.

Institutional Trading of Entera Bio

A number of institutional investors have recently made changes to their positions in ENTX. Schonfeld Strategic Advisors LLC increased its stake in Entera Bio by 5.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company’s stock valued at $1,157,000 after buying an additional 29,629 shares during the last quarter. Jane Street Group LLC lifted its position in Entera Bio by 142.6% during the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after buying an additional 43,536 shares in the last quarter. Renaissance Technologies LLC lifted its position in Entera Bio by 22.2% during the 4th quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock worth $210,000 after buying an additional 19,601 shares in the last quarter. HighTower Advisors LLC lifted its position in Entera Bio by 137.8% during the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock worth $84,000 after buying an additional 25,000 shares in the last quarter. Finally, Citadel Advisors LLC boosted its stake in shares of Entera Bio by 243.0% during the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock worth $77,000 after buying an additional 28,322 shares during the last quarter. Institutional investors own 14.11% of the company’s stock.

Wall Street Analyst Weigh In

ENTX has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Entera Bio in a report on Monday, February 9th. Wall Street Zen upgraded Entera Bio to a “sell” rating in a report on Saturday, December 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Entera Bio in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $10.00.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.